Please assess the completion status of the following clinical trial:

Trial Title: Rapid Switch From Flolan to Remodulin in the Outpatient Clinic

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Be between 18 years and 70 years of age~* Be male or if female, be physiologically incapable of childbearing or practicing an acceptable method of birth control (women of childbearing potential must have a negative pregnancy test).~* Have a current World Health Organization (WHO) functional classification of II-III status~* Diagnosis of one of the following WHO Classifications of pulmonary hypertension: Group 1 pulmonary arterial hypertension (IPAH, FPAH, APAH);Group 3 pulmonary hypertension associated with lung disease (Mild interstitial lung disease associated with predominant features of right heart failure as seen in Group 1 PAH patients); Group 4 pulmonary hypertension due to chronic thromboembolic pulmonary hypertension (CTEPH)~* In the opinion of the investigator, be hemodynamically stable with no signs or symptoms of disease progression~* Be receiving intravenous epoprostenol therapy for at least three months and a stable dose for at least one month prior to Baseline.~* Have a central intravenous catheter in place.~* Have a baseline six-minute walk distance of at least 150 meters.~* Be optimally treated with conventional pulmonary hypertension therapy and clinically stable for at least one month prior to baseline assessments.~* Be mentally and physically capable of learning to administer Remodulin using an intravenous infusion pump.~Exclusion Criteria:~* Be a nursing or pregnant woman~* Have had a new type of chronic therapy (including but not limited to oxygen, a different category of vasodilator, a diuretic, digoxin, bosentan, sildenafil) for pulmonary hypertension added within the last month.~* Have any PAH medication discontinued within the week prior to study entry.~* Received any prostacyclin or prostacyclin analog except epoprostenol in the past 3 months.~* Have an on-going central venous line infection within the past 30 days.~* Have evidence of predominant left-sided heart disease~* Have any other disease that is associated with pulmonary hypertension (e.g. sickle cell anemia, schistosomiasis).~* Have a musculoskeletal disorder (e.g. arthritis, artificial leg, etc.) or any other disease, which is thought to limit ambulation, or be connected to a machine, which is not portable.~* Have uncontrolled systemic hypertension as evidenced by a systolic blood pressure greater than 160 mmHg or diastolic blood pressure greater than 100 mmHg.~* Be receiving an investigational drug, have in place an investigational device, or have participated in an investigational drug study within the past 30 days.~* Have the presence of any physiological or psychological condition that contraindicates the administration of Remodulin.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- treprostinil sodium (Type: EXPERIMENTAL): all subjects had switched from IV epoprostenol to IV treprostinil sodium

Based on this trial design, predict the completion outcome and termination type (if applicable).